Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis

Naba R. Mainali, Vijaya R Bhatt, Shiksha Kedia, Jairam Krishnamurthy, Laura M. Wake, Mojtaba Akhtari

Research output: Contribution to journalArticle

Abstract

Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.

Original languageEnglish (US)
Pages (from-to)386-392
Number of pages7
JournalJournal of Oncology Pharmacy Practice
Volume20
Issue number5
DOIs
StatePublished - Oct 1 2014

Fingerprint

Primary Myelofibrosis
Interferons
Bone Marrow
Polycythemia Vera
Ribavirin
Chronic Hepatitis C
Virus Diseases
Hematologic Neoplasms
Therapeutics
Hepatitis C
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Keywords

  • Bone marrow aplasia
  • immunosuppression
  • myelosuppression
  • pancytopenia
  • pegylated interferon-α-2a
  • primary myelofibrosis

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis. / Mainali, Naba R.; Bhatt, Vijaya R; Kedia, Shiksha; Krishnamurthy, Jairam; Wake, Laura M.; Akhtari, Mojtaba.

In: Journal of Oncology Pharmacy Practice, Vol. 20, No. 5, 01.10.2014, p. 386-392.

Research output: Contribution to journalArticle

Mainali, Naba R. ; Bhatt, Vijaya R ; Kedia, Shiksha ; Krishnamurthy, Jairam ; Wake, Laura M. ; Akhtari, Mojtaba. / Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis. In: Journal of Oncology Pharmacy Practice. 2014 ; Vol. 20, No. 5. pp. 386-392.
@article{d2b990432f8446528d2b2cb6d6f354fc,
title = "Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis",
abstract = "Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.",
keywords = "Bone marrow aplasia, immunosuppression, myelosuppression, pancytopenia, pegylated interferon-α-2a, primary myelofibrosis",
author = "Mainali, {Naba R.} and Bhatt, {Vijaya R} and Shiksha Kedia and Jairam Krishnamurthy and Wake, {Laura M.} and Mojtaba Akhtari",
year = "2014",
month = "10",
day = "1",
doi = "10.1177/1078155213504444",
language = "English (US)",
volume = "20",
pages = "386--392",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis

AU - Mainali, Naba R.

AU - Bhatt, Vijaya R

AU - Kedia, Shiksha

AU - Krishnamurthy, Jairam

AU - Wake, Laura M.

AU - Akhtari, Mojtaba

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.

AB - Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.

KW - Bone marrow aplasia

KW - immunosuppression

KW - myelosuppression

KW - pancytopenia

KW - pegylated interferon-α-2a

KW - primary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84907218787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907218787&partnerID=8YFLogxK

U2 - 10.1177/1078155213504444

DO - 10.1177/1078155213504444

M3 - Article

C2 - 24067929

AN - SCOPUS:84907218787

VL - 20

SP - 386

EP - 392

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 5

ER -